Therapeutic Responses and Predictors of Low-Dose Interleukin-2 in Systemic Lupus Erythematosus

doi:10.21203/rs.3.rs-138441/v1

Download PDF

Research article

Therapeutic Responses and Predictors of Low-Dose Interleukin-2 in Systemic Lupus Erythematosus

https://doi.org/10.21203/rs.3.rs-138441/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 30 Jan, 2021

Read the published version in Clinical and Experimental Rheumatology →

Version 1

posted

You are reading this latest preprint version

Objective. Interleukin-2 (IL-2) is effective and well tolerated in patients with systemic lupus erythematosus (SLE). However, patient response to IL-2 therapy varies. Therefore, biomarkers are needed to efficiently identify patients who may respond well to IL-2 treat

ment. We investigated clinical and immunological biomarkers to predict low-dose IL-2 responses.

Methods. A pooled post-hoc analysis was performed in SLE patients who received low-dose IL-2 treatment in two clinical trials. Factors predicting responses in clinical and T-cell subset changes were evaluated by logistic regression. Good response (GR) and poor response (PR) were defined according to whether patients achieved or did not achieve an SLE Responder Index-4 (SRI-4), respectively.

Results. A good response at 68% of patients was achieved in the lower Treg group, compared to 0% in the higher Treg group. A good response at 68% was achieved in patients with lower Treg, compared to 0% in patients with higher Treg. In comparison to PR, GR was more strongly associated with low Treg proportions at baseline (12.85±6.07% vs. 9.43±2.82%, P<0.01). There were more patients with skin rash in the GR group than in the PR group (68.75% vs. 30.77%, P=0.042). Multivariate analysis showed that low Treg proportions and skin rash presence were both independently associated with GR to low-dose IL-2 treatment. A nomogram to identify GR probability exhibited a clear discrimination (concordance index, 0.812; 95% confidence interval, 0.64-0.97). Based on the area under the receiver operating characteristic (ROC) curve (AUC) of 0.813, the specificity of a low regulatory T cells (Tregs) proportion (≤13.35%) plus skin rash to predict GR to IL-2 therapy was 100%, with a sensitivity of 68.75%.

Conclusion. A low Treg proportion and skin rash indicate GR to low-dose IL-2 treatment in SLE patients.

Trial registration number ClinicalTrials.gov Registries ((NCT02465580 and NCT02084238).

Rheumatology

Interleukin-2 (IL-2)

Good response (GR)

SLE Responder Index-4 (SRI-4)

A low Treg proportion and skin rash indicate good responses to low-dose IL-2 treatment in SLE patients.
A nomogram was proposed to evaluate probability of clinical remission with low-dose IL-2.

Systemic lupus erythematosus (SLE) is characterized by a breakdown in immune tolerance, leading to auto-reactive immune responses and consequential tissue and organ damage. Regulatory T cells (Tregs) suppress autoimmunity and regulate innate and adaptive immune responses. Treg impairment is associated with a loss of immune tolerance and autoimmunity. Low-dose interleukin-2 (IL-2) has been studied as an immunoregulatory agent that selectively promotes Treg expansion, showing promising efficacy in the treatment of SLE [1–4]. However, these clinical studies showed that a substantial proportion of SLE patients had a sub-optimal response to low-dose IL-2 and failed to achieve an SLE Responder Index-4 (SRI-4) at the end of their IL-2 treatment period. To date, the prediction of response to IL-2 therapy is not well studied in SLE. It was found that increase of the CD25hi-expressing cells among CD3 + CD4 + Foxp3 + CD127lo Tregs might be suggestive of clinical responsiveness to low-dose IL-2 treatment [3]. However, indicators evaluated after the therapy were limited in their ability to guide therapeutic decision. In practice, baseline biomarkers are more valuable to guide treatment choices. In this study, we analyzed multiple clinical and laboratory parameters to identify baseline markers to predict response to IL-2.

Participants This study was to analyze the therapeutic responses to low-dose IL-2 in a randomized controlled trial (RCT) (NCT02465580) of 29 SLE patients as primary cohort. Then, the prediction model was validated by using an independent cohort with 23 patients (NCT02084238). Full details of study designs and inclusion/exclusion criteria for each completed study have previously been published [1, 2]. Studies were conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonization Guidelines for Good Clinical Practice, and local regulations.

All the patients were treated for the first 12 weeks which included three treatment cycles with IL-2 along with standard treatment, and followed up for further 12 weeks without IL-2. Patients were evaluated at screening and every 4 weeks up to week 24. The primary efficacy endpoint was the attainment of an SRI-4 at week 12 in both trials.

The primary cohort for the development of the nomogram was the low-dose IL-2 group in trial 1, and the independent validation cohort comprised the patients with IL-2 immunological analyses in IL-2 group in trial 2. The performance of the internally validated nomogram was tested again in the validation cohort. The logistic regression formula formed in the primary cohort was applied to all patients in the validation cohort, and the total points were calculated for each patient. In this cohort, logistic regression was then performed by using the total points as a factor. Finally, the concordance index (c-index) was derived on the basis of the regression analysis.

Statistical analysis Descriptive statistics are provided as the mean ± the standard deviation (SD), median (interquartile range (IQR) (p25 to p75)) or n (%) depending on data distribution. Differences in baseline characteristics between SRI-4 vs. non-SRI-4 groups were compared using a Student’s t-test (or, if not normally distributed, the Wilcoxon rank-sum test) and the χ2 test for continuous and categorical data, respectively. Baseline items showing significant associations in simple (univariable analysis) models qualified for further analysis in multiple logistic regression models for the assessment of priority, independence and confounding potentiality. We developed models for the prediction of SRI-4 responses using multiple imputation multivariable logistic regression. We tested the accuracy of the clinical model by comparison of the area under the receiver operator characteristic (ROC) curve (AUC) in both the primary cohort and the validation cohort. Statistical analyses were performed using SPSS v.22.0 or R v.3.6.3 software. Two-sided P values < 0.1 were considered statistically significant.

Characteristics of patients and comparisons of responses to IL-2 therapy

Characteristics of the patients in the primary and validation cohorts are shown in Table S1. Patients were divided into those with good response (GR) and those with poor response (PR) according to whether they achieved or did not achieve an SRI-4, respectively, at week 12. Sixteen patients (55.17%) had GR to low-dose IL-2 treatment, whereas 13 patients had PR.

In comparison to PR, GR was more strongly associated with low Treg proportions (12.85 ± 6.07% vs. 9.43 ± 2.82%, P = 0.01) and low Treg/Th17 ratios at baseline (0.79 ± 0.35% vs. 0.51 ± 0.21%, P = 0.02) (Table 1). There were more patients with skin rash in the GR group (68.75%, 11/16) than in the PR group (30.77%, 4/13) (P = 0.042) (Table 1).

Table 1

Univariate analysis and multivariate logistic regression analysis of the probability of an SRI-4 response in cohort 1.
Variable	SRI-4		Univariate analysis	Multivariate analysis
Variable	Poor responders (n = 13)	Good responders (n = 16)	P	RR	95% CI	P
Sex (female), n (%)	11 (84.62)	15 (93.75)	0.421	-	-	-
Age (years)	34.00 ± 12.70	30.13 ± 8.24	0.35	-	-	-
Duration (months)	20.5 (3.5, 85.5)	55 (39, 103.5)	0.13	-	-	-
SLEDAI score	11.62 ± 4.94	11.88 ± 4.03	0.88	-	-	-
Skin rash, n (%)	5 (35.71)	11 (73.33)	0.042	0.08	0.01–0.66	0.02
Routine laboratory tests
WBC (*10⁹/L)	5.43 ± 1.88	5.88 ± 3.00	0.63	-	-	-
HGB (g/L)	121.0 ± 22.10	123.0 ± 19.00	0.80	-	-	-
PLT (*10⁹/L)	173.2 ± 66.07	206.7 ± 91.68	0.26	-	-	-
Lymphocytes (*10⁹/L)	1.24 ± 0.57	1.35 ± 0.80	0.69	-	-	-
24 h-UPE (g/day)	0.39 (0.12, 1.8)	0.14 (0.09, 0.64)	0.20	-	-	-
Serum creatinine (µmol/L)	77.82 ± 42.96	55.70 ± 9.42	0.12	-	-	-
Uric acid (µmol/L)	347.1 ± 131.26	271.59 ± 91.84	0.11	-	-	-
GFR (ml/min)	102.47 ± 32.80	119.82 ± 12.46	0.11	-	-	-
Albumin (g/L)	38.29 ± 7.18	41.62 ± 4.08	0.19	-	-	-
ESR (mm/h)	20 (7, 44)	14 (8.5, 28)	0.20	-	-	-
CRP (mg/L)	2.38 (0.58, 8.39)	1.3 (0.53, 5.04)	0.42	-	-	-
C3 (G/L)	0.79 ± 0.32	0.83 ± 0.23	0.71	-	-	-
C4 (G/L)	0.17 ± 0.11	0.15 ± 0.04	0.53	-	-	-
Antibodies
Anti-ANA	320 (320, 640)	320 (80, 400)	0.61	-	-	-
Anti-AnuA	43.44 (4.32, 142.8)	12.83 (0.87, 40.01)	0.16	-	-	-
Anti-dsDNA	84 (19.8, 260.4)	36.1 (18.88, 64.1)	0.13	-	-	-
Anti-Sm	1 (12.5)	3 (25)	0.33	-	-	-
Immune cells
CD4⁺T (% in CD3⁺T)	45.56 ± 14.00	44.08 ± 9.62	0.75	-	-	-
CD8⁺T (% in CD3⁺T)	46.35 ± 15.53	48.68 ± 8.79	0.64	-	-	-
Treg (% in CD4⁺T)	12.85 ± 6.07	9.43 ± 2.82	0.01	0.70	0.48–1.01	0.055
Teff (% in CD4⁺T)	87.47 ± 7.19	86.93 ± 14.00	0.89	-	-	-
Th17 (% in CD4⁺T)	15.11 ± 7.69	19.92 ± 9.13	0.14	-	-	-
Treg/Th17	0.79 ± 0.35	0.51 ± 0.21	0.02	-	-	-
Treg/Teff	0.15 ± 0.10	0.20 ± 0.41	0.62	-	-	-
B (% in lymphocyte)	3.71 ± 2.90	5.16 ± 5.39	0.43	-	-	-
NK (% in lymphocyte)	6.03 ± 4.96	6.39 ± 4.86	0.85	-	-	-
Treg (cells/L)	13.96 ± 7.9	12.81 ± 7.11	0.69	-	-	-
Cytokines
IFN-α (pg/ml)	5.28 (2.92, 10.49)	4.74 (2.67, 9.35)	0.30	-	-	-
IL-2 (pg/ml)	1.85 (1.32, 2.95)	2.07 (1.64, 3.24)	0.27	-	-	-
IL-21 (pg/ml)	1.68 (0.96, 4.85)	1.55 (0.27, 3.29)	0.43	-	-	-
IFN-γ (pg/ml)	1.06 (0.78, 1.31)	1.01 (0.72, 1.23)	0.49	-	-	-
IL-17 (pg/ml)	0 (0, 0.61)	0 (0, 0.03)	0.19	-	-	-
IL-10 (pg/ml)	2.75 (2.07, 3.94)	2.85 (2.13, 3.85)	0.89	-	-	-
TGF-β (pg/ml)	50870 (26736, 75191)	60131 (26848, 92819)	0.51	-	-	-
Data are presented as the median (range) or the mean ± standard deviation (SD) for continuous variables and as the count (percentage) for categorical variables. Good responders were defined as patients who achieved a Systemic Lupus Erythematosus (SLE) Responder Index-4 (SRI-4), while poor responders were defined as patients who did not achieve an SRI-4. CI, confidence interval. SLEDAI, SLE Disease Activity Index. WBC, white blood cell. HGB, hemoglobin. PLT, platelet. 24 h-UPE, urine protein excretion per 24 hour. GFR, glomerular filtration rate. ESR, erythrocyte sedimentation rate. CRP, C-reactive protein. C3, complement 3. C4, complement 4. Anti-AnuA, anti-nucleosome antibody. Anti-dsDNA, anti-double-stranded DNA antibody. Treg, regulatory T cell. Teff, effector T cell. Treg#, absolute number of Tregs. IFN-α, interferon-α. IL-2, interleukin-2. IL-21, interleukin-21. IFN-γ, interferon-γ. IL-10, interleukin-10. TGF-β, transforming growth factor-β.. ANA, Anti-nuclear antibody. Sm, Anti-Sm antibody.

A multivariate logistic regression analysis was performed using all factors associated with GR in the univariate analysis. A lower Treg proportion and skin rash were independently associated with GR to low-dose IL-2 treatment (P = 0.055 and P = 0.02, respectively, Table 1).

Low Treg Proportion Predicts Clinical Response To Il-2 Treatment

We divided SLE patients who received IL-2 treatment into two groups, i.e. those with a low or high proportion of Tregs, according to a cutoff value of 13.35%, calculated by ROC with an AUC of 0.73 (Fig. 1A). The subsequent analysis suggested that patients with a low proportion of Tregs had a three times higher probability of achieving GR to IL-2 treatment than patients with a high proportion of Tregs (P = 0.011) (Table 2).

Table 2

The predicative of Treg or Treg/Th17 on SRI-4 in primary cohort.
		Poor responders SRI-4(-)	Good responders SRI-4(+)	RR	P
Treg	≤ 13.35	8	16	3	0.011
Treg	> 13.35	5	0	3	0.011
SRI-4, Systemic Lupus Erythematosus (SLE) Responder Index-4. RR, relative risk.

A good response at 68% of patients was achieved in the low Treg group at week 12, compared to 0% in the high Treg group. In the follow-up period, 88% of patients in the low Treg group achieved GR at week 24 at end of the follow-up, compared to 0% in the high Treg group (Fig. 1B). The proportion of patients who achieved complete renal remission (CR) was significantly higher in the low Treg group than in the high Treg group at week 12 (33.33% vs. 0%) and week 24 (40% vs. 0%) (Fig. 2A). The low Treg group had a lower 24 h urine protein excretion (24 h-UPE) at week 24 than the high Treg group (0.83 ± 0.51 vs. 0.94 ± 0.49, P = 0.093) (Fig. 2B). The proportion of patients achieved 50% steroid tapering was also significantly higher in the low Treg group than that in the high Treg group at week 12 (44% vs. 0%) and week 24 (52% vs. 0%) (Fig. 1C).

Modeling and validation

To further clarify the application of these predictive markers, a nomogram was developed to estimate the likelihood of GR to low-dose IL-2 treatment in each individual patient (Fig. 3). The adjusted c-index for predicting GR in the primary cohort was 0.812, ranging from 0.64 to 0.97. In the independent validation procedure, the c-index was 0.776, ranging from 0.49 to 1.06 and thus showing good discrimination ability across all patients. Besides, the AUC for the combined model (i.e., the proportion of Tregs and the presence of skin rash) was 0.813, with the sensitivity of 68.75% and 100% specificity (Fig. 1A).

CD4 + Tregs play a central role in immune tolerance, and Treg dysfunction is well described in autoimmune disorders. In vivo, Treg expansion through low-dose IL-2 treatment has been reported in a number of diseases, including chronic graft-versus-host disease (cGVHD), type 1 diabetes, SLE and several other autoimmune diseases (AIDs) [1–7]. These studies indicated that this treatment is well tolerated and effective, but prediction of patients who may have a better response to low-dose IL-2 is still a challenge in clinical practice.

Previous studies showed low Tregs and IL-2 in the circulation of SLE patients and the efficacy of low-dose IL-2 treatment. In this study, we proved that a low proportion of Tregs and the presence of skin rash could be predictors of responses to low-dose IL-2 therapy in SLE patients.

Increase of CD25hi-expressing Tregs was associated with clinical responsiveness to low-dose IL-2 [3]. However, post-treatment indicator would not help decision making by clinicians. Our findings in this study support the utility of the baseline Treg and skin rash before IL-2 administration to predict SRI-4 response. We also built a predictive model, which may help clinicians in decision making. The model indicated that Treg ≤ 13.35% plus skin rash presence predicted GR to IL-2 therapy with 100% specificity and 68.75% sensitivity. In addition, there was a trend that serum IL-2 and IL-10 levels were decreased in the SRI-4 responder group, although not statistically significant. This difference may become statistically significant with a larger sample size.

It remains unclear why there is a subgroup appearing to benefit more from low-dose IL-2. Low number of Treg cells was found in skin lesion of patients with cutaneous erythematosus [8]. Low-dose interleukin‑2 specifically expands Treg cells to confer immunosuppressive capacity to autoimmune response and inflammation. A limitation of this study is the small sample size.

In summary, we found in a pooled post-hoc analysis that a low Treg proportion and skin rash indicated good response to low-dose IL-2 treatment in SLE patients.

IL-2: Interleukin-2; SLE: systemic lupus erythematosus; GR: good response; PR: poor response; SRI-4: systemic lupus erythematosus responder index-4; ROC: receiver operating characteristic; AUC: area under the receiver operating characteristic curve; Tregs: regulatory T cells; RCT: randomized controlled trial; c-index: concordance index; 24h-UPE: 24h urine protein excretion; cGVHD: chronic graft-versus-host disease; AIDs: autoimmune diseases; VSMCs: vascular smooth muscle cells.

Acknowledgements

We acknowledge the patients, research nurses and clinicians who helped support this study.

Authors’ contributions

ZGL and XS contributed to the study conception and design. XS, JH and MM contributed to the data interpretation and analysis. All authors contributed to the acquisition of data, drafting and revising the manuscript and have critically reviewed and approved the final submitted version to be published.

Funding

The National Natural Science Foundation of China (31870879, 81971520), Peking-Tsinghua Center for Life Sciences, Peking University Clinical Scientist Program (BMU2019LCKXJ004) and Clinical Medicine Plus X-Young scholars Project of Peking University (PKU2020LCXQ018) supported by the Fundamental Research Funds for the Central Universities.

Ethics approval and consent to participate

This study was approved the Human Ethics Committee of Peking University People’s Hospital (Beijing, China) and all subjects provided written informed consent.

Consent for publication

Not applicable.

Disclosure statement

The authors have declared no conflicts of interest.

Data availability statement

Data are available upon reasonable request.

Author details

¹ Department of Rheumatology & Immunology, Peking University People's Hospital, Beijing, 100044, China.

² Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135).

ORCID iD

Zhanguo Li https://orcid.org/0000-0002-2590-6242

Xiaolin Sun https://orcid.org/0000-0001-9709-1532

Jing He https://orcid.org/0000-0003-3904- 8928.

He J, Zhang R, Shao M, Zhao X, Miao M, Chen J, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2020;79:141–9.
He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016;22:991–3.
Humrich JY, Spee-Mayer C, Siegert E, Bertolo M, Rose A, Abdirama D, et al. Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. The Lancet Rheumatology. 2019;1:e44–54.
Rosenzwajg M, Lorenzon R, Cacoub P, Pham HP, Pitoiset F, El Soufi K, et al. Immunological and clinical effects of low-dose interleukin-2 across 11autoimmune diseases in a single, open clinical trial. Ann Rheum Dis. 2019;78:209–17.
Miao M, Hao Z, Guo Y, Zhang X, Zhang S, Luo J, et al. Short-term and low-dose IL-2 therapy restores the Th17/Treg balance in the peripheral blood of patients with primary Sjögren’s syndrome. Ann Rheum Dis 2018; 213036.
Zhang SX, Wang J, Sun HH, Zhang JQ, Liu GY, Luo J, et al. Circulating regulatory T cells were absolutely decreased in dermatomyositis/polymyositis patients and restored by low-dose IL-2. Ann Rheum Di 2019; 216246.
Wang J, Zhang SX, Hao YF, Qiu MT, Luo J, Li YY, et al. The numbers of peripheral regulatory T cells are reduced in patients with psoriatic arthritis and are restored by low-dose interleukin-2. Ther Adv Chronic Dis. 2019;11:204062232091601.
Franz B, Fritzsching B, Riehl A, Oberle N, Klemke CD, Sykora J, et al. Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus. Arthritis Rheum. 2007;566:1910–20.

Supplementarytable2020.12.20.doc

Download PDF

Journal Publication

published 30 Jan, 2021

Read the published version in Clinical and Experimental Rheumatology →

Version 1

posted

You are reading this latest preprint version

Therapeutic Responses and Predictors of Low-Dose Interleukin-2 in Systemic Lupus Erythematosus

Status:

Journal Publication

Version 1

Abstract

Figures

Key Messages

Introduction

Methods

Results

Characteristics of patients and comparisons of responses to IL-2 therapy

Low Treg Proportion Predicts Clinical Response To Il-2 Treatment

Modeling and validation

Discussion

Conclusion

Abbreviations

Declarations

References

Supplementary Files

Status:

Journal Publication

Version 1